Compare Teucrium Corn Fund (CORN) vs CVS Health Corp (CVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Teucrium Corn Fund vs CVS Health Corp — how do they compare? Teucrium Corn Fund trades at $18.42 (market cap $125.39M), while CVS Health Corp trades at $86.16 (market cap $112.29B). The key difference: CVS Health Corp is far larger — about 895.5× Teucrium Corn Fund's market cap, and CVS Health Corp pays a 3.03% dividend while Teucrium Corn Fund pays none. Which is the better fit depends on your goals — on Pluang, investors hold Teucrium Corn Fund for 27 Days and CVS Health Corp for 83 Days on average.
| CORN | CVS | |
|---|---|---|
Market Cap | $125.39M | $112.29B |
Volume | 271,634 | 7,763,676 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $20.29 | $110.60 |
52-Week Low | $16.46 | $70.08 |
Typical Hold Time | 27 Days | 83 Days |
Enterprise Value | — | $174.64B |
Dividend Yield | — | 3.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CORN (Teucrium Corn Fund) is trading at $18.42, down 3.31% with bearish technical indicators showing 13 sell signals versus 7 buy signals. The fund recently demonstrated strong performance with a 9.7% return in July 2026, outperforming broader markets. Current technical analysis indicates oversold conditions with RSI at 29.02, while moving averages remain bearish. Agricultural commodities face mixed sentiment amid ongoing inflation concerns and geopolitical tensions affecting global supply chains.
The outlook for CORN reflects commodity market volatility with potential upside from agricultural sector strength but significant downside risk from macroeconomic pressures. Investment opportunity exists in agricultural commodity exposure, though risks include inflation trajectory, Federal Reserve policy, and geopolitical conflicts that could disrupt global corn markets and fund performance.
CVS Health trades at $87.80, down 0.17% on the day, with a bearish technical signal and neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $2.58 exceeding the $1.85 estimate. Revenue grew to $402.07B in 2025, though net income margin compressed to 1.18%. Recent news highlights Aetna's 2027 Medicare plan updates and a quarterly dividend declaration.
CVS presents a mixed outlook with solid revenue growth and analyst bullishness (85% buy ratings, $111.20 consensus target) offset by profitability pressures and a bearish technical trend. Key risks include reimbursement pressure and ongoing legal investigations, but the stock offers value with a low P/S of 0.27 and dividend yield support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Teucrium Corn Fund
CORN is a commodity ETF that provides exposure to the price of corn futures. It uses a laddered investment strategy across multiple benchmark contracts to help minimize the impact of contango and roll costs in the agricultural market.
Read more on CORN →About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →
